CAS: 443797-96-4; 4-((5-Amino-1-(2,6-Difluorobenzoyl)-1H-1,2,4-Triazol-3-yl)Amino)Benzenesulfonamide

上下游产品

CAS号172935-91-0 2,6-二氟苯甲酰肼 | CAS号79463-77-7 N-氰基羰亚胺二苯基酯 | CAS号63-74-1 磺胺 | CAS号700805-72-7 N-[4-(aminosulf... | CAS号443799-31-3 4-(5-amino-1H-[... | CAS号18063-02-0 2,6-二氟苯甲酰氯 | CAS号51908-29-3 4-异硫氰基苯磺酰胺

Phenyl-N'-Cyano-N-(4-Sulfamoylphenyl)Carbamimidate置于吡啶,肼体系中,用 四氢呋喃 作为反应溶剂,化学反应 8.0H,反应生成 Aurora激酶
参考文献:1-Acyl-1H-[1,2,4]Triazole-3,5-Diamine Analogues As Novel And Potent Anticancer Cyclin-Dependent Kinase Inhibitors: Synthesis And Evaluation Of Biological Activities
标题:1-Acyl-1H-[1,2,4]Triazole-3,5-Diamine Analogues As Novel And Potent Anticancer Cyclin-Dependent Kinase Inhibitors: Synthesis And Evaluation Of Biological Activities
摘要:A Series Of 1-Acyl-1H-[1,2,4]Triazole-3,5-Diamine Analogues Were Synthesized As Cyclin-Dependent Kinase (Cdk) Inhibitors. These Compounds Showed Potent And Selective Cdk1 And Cdk2 Inhibitory Activities And Inhibited In Vitro Cellular Proliferation In Various Human Tumor Cells. Representative Compound 3B Demonstrated In Vivo Efficacy In A Human Melanoma A375 Xenograft Model In Nude Mice.
DOI:10.1021/jm050267E

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.